Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker CTD_human The long tail of oncogenic drivers in prostate cancer. 29610475

2018

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of <i>TP53</i> Missense Mutation in Prostate Cancer. 28446506

2018

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53-</i>Deficient Prostate Cancer to Radiation. 28500233

2018

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE Mutations in the p53 tumor suppressor are frequent in patients with castration-resistant prostate cancer but less so in patients with localized disease, and patients who have Li-Fraumeni with germline p53 mutations do not have an increased incidence of prostate cancer, suggesting that additional molecular and/or genetic changes are required for p53 to promote prostate carcinogenesis. 29029019

2017

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker CTD_human Integrative molecular profiling of routine clinical prostate cancer specimens. 25735316

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 AlteredExpression BEFREE Mechanistically, CUL4A could modulate the expression of P53 in PCa cells. 26036759

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. 26694174

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 GeneticVariation BEFREE Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients. 24448834

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE The identification of the alternative reading frame protein (ARF) / murine double minute protein (MDM2) / p53 tumour suppressor pathway potentially involving the IL-6/STAT3 axis as a restricting factor in prostate cancer deficient in the tumour suppressor phosphatase and tensin homologue (PTEN) opened new avenues to currently available therapies. 26691865

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE Mechanism dissection revealed that infiltrated mast cells could increase p21 expression via modulation of p38/p53 signals, and interrupting p38-p53 signals via siRNAs of p53 or p21 could reverse mast cell-induced docetaxel chemotherapy resistance of PCa. 26625310

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 GeneticVariation BEFREE Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations. 26512780

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer. 26900800

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 GeneticVariation BEFREE Here we use a sensitized, non-metastatic Pten/Trp53-mutant RapidCaP system for functional validation of human metastasis drivers in a much accelerated time frame of only 3-4months. 25592467

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. 25296977

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 GeneticVariation BEFREE Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. 26000489

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE Inactivation of p19(Arf) reduces Slug levels, resulting in increased E-cadherin expression and delaying the onset and progression of prostate cancer in Pten/Trp53 double null mice. 24910389

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 AlteredExpression BEFREE Clonogenic survival analyses indicated that micromolar concentrations of niraparib radiosensitized tumor cell lines derived from lung, breast, and prostate cancers independently of their p53 status but not cell lines derived from normal tissues. 24970803

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker CTD_human Spatial genomic heterogeneity within localized, multifocal prostate cancer. 26005866

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE PIM inhibition is a potential treatment for MYC-driven prostate cancers including CRPC, and its effectiveness may be enhanced by activators of the p53 pathway, such as radiation. 25505253

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE Met was amplified in 67% of prostate tumors from Pten p53 prostate conditional null mice and in approximately 30% of metastatic human prostate cancer specimens, often in association with loss of PTEN and TP53. 25381262

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE Furthermore, we also provide evidence that Plk1 inhibition makes PCa cells carrying WT p53 much more sensitive to low-dose metformin treatment. 25505174

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE In support of the functional interaction between CD24 and p53, in silico analyses reveal that TP53 mutates at a higher rate among glioma and prostate cancer samples with higher CD24 mRNA levels. 25600590

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 Biomarker BEFREE MYC, BIRC5/survivin, CDC25 and P53 may contribute to PC risk. 25770188

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 AlteredExpression BEFREE Given the important roles of tumor suppressor p53 in regulating sensitivity of tumor cells to chemotherapeutics, we performed studies in two human prostate cancer cell lines differing in p53 expression: LNCaP cells (wild-type p53) and PC-3 cells (p53-null). 25253786

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.500 GeneticVariation BEFREE Specific genes involved in the DDR such as BRCA1/2 and P53 are mutated during prostate cancer progression, while various oncogenic signaling such as Akt and c-Myc are activated, enhancing the replication stress and increasing the genomic instability of cancer cells. 25132269

2015